ARCALIS Inc. (headquartered in Minamisoma City, Fukushima Prefecture; hereinafter “ARCALIS”) is pleased to announce that its new mRNA Drug Substance Plant (hereinafter “NEW PLANT”) under construction in Minamisoma City, Fukushima Prefecture was completed on July 31^st, 2023, and a completion ceremony was held today, August 4^th, 2023.

The NEW PLANT will meet the current Good Manufacturing Practice (cGMP) standards and has been equipped with the world’s most advanced manufacturing and quality control systems. We are committed to meeting a variety of customers’ demands.

【Description】

Name	ARCALIS Minamisoma Drug Substance Plant
Address	320-20 Kawauchisako, Shimoota aza, haramachi, Minamisoma, Fukushima, 975-0041
Structure	Steel frame, 5 floor, seismically isolated (36 meters)
Building Area	1933 m2
Total floor space	7252 m2
Outline of Plant Facilities	Equipped with the manufacturing facilities necessary to produce mRNA, a cutting-edge pharmaceutical product, for overseas use in compliance with cGMP
Manufacturing Items	mRNA and LNP in bulk
Production Capability	Up to 5 kg of Drug Substance per year in bulk
Estimated launch　date of full-scale operation	August 2023
Construction, design and management in charge	Obayashi Corporation

About ARCALIS　 https://corp.arcalis.co.jp/en

ARCALIS is an mRNA vaccines and therapeutics contract development and manufacturing organization (“CDMO”), jointly established by Axcelead, Inc. (President & CEO, Yoshinori Ikeura, hereafter, Axcelead) and Arcturus Therapeutics, Inc. (NASDAQ: ARCT/hereafter, Arcturus). ARCALIS aims to develop the world’s first mRNA vaccines and therapeutics CDMO business that promises a stable supply of high-quality mRNA medicines to all customers, including pharmaceutical companies, biotech companies, and academic

institutes worldwide. The new facility in the city of Minamisoma (Fukushima Prefecture) is equipped with state-of-the-art manufacturing and quality control systems that meet the cGMP standards for pharmaceuticals.

１．NEW PLANT

２．Future Vision of Minamisoma Plant

Press Release in English